Cytek Biosciences (CTKB) vs InMode (INMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytek Biosciences (CTKB) has outperformed InMode (INMD) over the past year, gaining 40.9% versus a loss of 6.8%. Over five years, CTKB leads with a -77.8% price change compared with -83.2% for INMD. InMode is the larger company by market cap ($806.2 million vs $694.1 million), about 1.2 times the size.
On valuation, InMode trades at a lower forward P/E (10.2x vs 76.3x for Cytek Biosciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | INMD |
|---|---|---|
| Share price | $5.34 | $14.01 |
| Market cap | $694.11M | $806.19M |
| 1-day change | -0.74% | +0.14% |
| YTD return | +5.74% | -4.63% |
| 1-year return | +40.90% | -6.79% |
| 5-year return | -77.81% | -83.20% |
| P/E ratio (TTM) | — | 11.58 |
| Forward P/E | 76.29 | 10.21 |
| EPS (TTM) | $-0.62 | $1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.21 | $16.74 |
| 52-week low | $3.31 | $12.72 |
| Distance from 52-week high | -14.01% | -16.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +4.12% | +15.42% |
| Average volume | 1.04M | 521.98K |
| Shares outstanding | 129.98M | 57.54M |
| Employees | 682 | 660 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTKB has outperformed INMD by 47.7 percentage points over the past year.
- The two companies sit in different sectors: Cytek Biosciences in Industrials and InMode in Health Care.
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
About InMode
INMD stock →InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 660 employees
CTKB vs INMD FAQ
Which is bigger, Cytek Biosciences or InMode?
InMode (INMD) is larger, with a market capitalization of $806.19M compared with $694.11M for Cytek Biosciences (CTKB).
Which stock has performed better over the past year, CTKB or INMD?
CTKB returned +40.90% over the past 12 months, compared with -6.79% for INMD (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and InMode in the same industry?
No. Cytek Biosciences is in the Industrials sector, while InMode is in Health Care.